Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2010

View Archived Issues

Eisai reports third quarter 2009 results

Prolor reports topline results from phase I study of CTP-modified human growth hormone

ChemoCentryx initiates phase I clinical trial of CCX-168 for autoimmune diseases

FDA approves Beech Tree's IND for phase I/IIa clinical trial of influenza drug BTL-TML-001

In vivo antiatherosclerotic effects of liver-selective thyromimetic support its clinical evaluation

Figitumumab safe and effective in phase I trial in adrenocortical carcinoma patients

Good safety profile of ciclosporin seen in severe traumatic brain injury patients

Conatus initiates phase II trial of CTS-1027 in combination with Pegasys and Copegus in HCV

Vertex reports preliminary results from phase IIa clinical trial of VX-809 in cystic fibrosis

GlaxoSmithKline discloses new agents for treating Flaviviridae virus infections

Faes Farma discloses novel anti-inflammatory compounds

Swissmedic approves BTG's DigiFab for life-threatening digitalis intoxication

Allergan presents new prostanoid EP2 receptor agonists

FDA accepts for filing Teva's BLA for XM-02 in neutropenia

Nano-sized conjugates with antiangiogenic activity disclosed by Ramot

Novel HDAC inhibitors identified by Karus Therapeutics

Isogenica and Phylogica sign partnership agreement for CIS display and Phylomer peptides

Apeiron and GSK sign agreement for enzyme biotherapeutic APN-01 for ARDS

Compugen discovers CGEN-15001 for treatment of autoimmune disorders

Stem Cell Therapy International and Histostem complete merger

ACT and University of Louisville sign agreement for identification of cancer drug candidates

United Therapeutics and Mondobiotech enter into global strategic partnership for aviptadil

Tanezumab relieves pain in three chronic conditions

Tapentadol IR and ER can be converted to equivalent daily doses

FDA approves Keryx's SPA for phase III X-PECT trial of perifosine in colorectal cancer

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...